SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors keenly await the outcome of a contentious city council vote in Independence, Missouri, regarding a crucial data center tax abatement, while simultaneously grappling with broader market pressure stemming from a competitor's recent disappointing earnings report.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp. is trending sharply upward as escalating geopolitical tensions in the Middle East drive a surge in oil prices and concerns over the Strait of Hormuz. The community is heavily focused on a potential massive short squeeze, citing the stock's low float and extremely high cost to borrow.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is actively discussed as NVIDIA's increased emphasis on optical interconnects validates the photonics sector, while a disclosed institutional stake and recent company updates detailing upcoming larger customer engagements for AI solutions amplify bullish sentiment.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as its full-year 2025 financial results reveal record revenue and substantial profitability improvements, igniting community debate over the stock's undervaluation compared to its expanding AI infrastructure pipeline, while many accuse shorts of actively suppressing the price despite strong fundamentals.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment Inc. (AVAV) is sharply lower after a Raymond James downgrade, citing recompetition for a key Space Force contract, triggered a massive intraday sell-off and intensified community debate over market manipulation.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following a sharp decline in its share price after reporting strong quarterly results but providing weaker-than-anticipated Q1 guidance and announcing key leadership departures. This has sparked a divided community discussion, with some viewing the drop as an overreaction and a buying opportunity, while others anticipate further downside due to concerns over growth deceleration and the evolving impact of AI.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT (LASR) is trending as its high-energy laser technology gains significant attention, validated by the effectiveness of systems like Israel's Iron Beam in recent conflicts. The community is buzzing with speculation about substantial new defense contracts, including the potential 'Golden Dome' project, fueling a strong bullish outlook on the company's strategic pivot to aerospace and defense.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd is trending with high volume and price appreciation due to escalating Middle East tensions, including threats to the Strait of Hormuz and attacks on regional energy infrastructure, leading the community to speculate on its continued upside compared to other oil plays.

Dave, Inc. is a digital banking service. Its products include a budgeting tool to help members manage their upcoming bills to avoid overspending, cash advances through its flagship ExtraCash product to help members avoid punitive overdraft fees, a Side Hustle product, where Dave helps connect members with supplemental work opportunities, and Dave Banking, a modern checking account experience with valuable tools for building long-term financial health. The company was founded by Jason Wilk, Paras Chitrakar, and John Wolanin in October 2015 and is headquartered in Los Angeles, CA.

Dave Inc - Ordinary Shares - Class A

Dave Inc. is trending following its strong Q4/FY25 earnings report, which highlighted robust revenue growth and increased profitability, exciting the community with ambitious 2026 guidance and a significant boost to its share repurchase program, fueling discussions about its current undervaluation and potential for a substantial re-rating.

Carpenter Technology Corp. engages in the manufacturing, fabrication, and distribution of specialty metals. It operates through the Specialty Alloys Operations and Performance Engineered Products segments. The Specialty Alloys Operations segment is composed of its major premium alloy and stainless-steel manufacturing operations. The Performance Engineered Products segment includes the Dynamet titanium, Carpenter Additive, and the Latrobe and Mexico distribution businesses. The company was founded by James Carpenter in 1889 and is headquartered in Philadelphia, PA.

Carpenter Technology Corp.

Carpenter Technology (CRS) is trending amid strong earnings and increased guidance, driven by robust demand for its high-spec alloys across aerospace, defense, medical, energy, and AI data center markets. The community sees it as a "Fortress America" stock, actively discussing its undervaluation, potential for a stock split or acquisition, and strong fundamentals propelling new highs, despite some skepticism about its current valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio (NASDAQ:IBRX) Trading 6.7% Higher Following Better-Than-Expected Earnings

ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.7% Following Earnings Beat...

Biotech Stocks To Follow Today - March 2nd

Danaher, Moderna, and ImmunityBio are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and...

ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors purchased 48,270 call options on the company. This represents an...

<ul class="summary-bullets"><li>The company's 2025 outlook shows EBIT loss narrowing to $256.03 million from $344.18 million a year ago.</li><li>Anktiva commercialization is driving traction, with 2025 net product revenue reaching $113 million, up 700% from the previous year.</li><li>ImmunityBio's Phase 2 Quilt 2.005 data shows higher cancer-free rates and a potential BLA filing expected by Q4.</li></ul>Shares of ImmunityBio, Inc. (IBRX) jumped 1% in overnight trading Sunday as investors positioned ahead of Tuesday’s earnings, with fresh weekend buzz around Anktiva following founder Patrick Soon-Shiong’s media appearances.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped over 2% on Friday to $0.78 and added another 5% in after-hours trading.&nbsp;<h2 class="st-heading-2">Earnings Expectations Take Center Stage</h2>ImmunityBio is set to report its full-year 2025 earnings on Tuesday, with expectations building that losses may narrow as the company scales commercialization of Anktiva, its lead immunotherapy.Fiscal AI estimates for 2025 show an improvement across all metrics. Revenue is projected to rise to $113.29 million from $14.75 million in 2024, while earnings before interest and taxes (EBIT)&nbsp;are expected to narrow to a loss of $256.03 million from $344.18 million a year ago. Loss per share is forecast to improve to $0.38 from $0.59 in 2024.The company has already indicated strong commercial traction&nbsp;for Anktiva, recording $113 million in net product revenue for the drug in 2025, up 700% from the prior year, while fourth-quarter (Q4) revenue rose 431% to $38.3 million, topping Wall Street estimates of $37.8 million.Despite higher research spending pushing Q4 net loss to $61.9 million from $59.2 million, full-year net loss attributable to common shareholders improved to $351.4 million from a loss of $413.6 million in 2024.<h2 class="st-heading-2">Founder Highlights Anktiva On National TV</h2>Over the weekend, founder and executive chairman Patrick Soon-Shiong amplified the scientific importance of Anktiva through a series of national&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-retail-frenzy-founder-prime-time-tv-blitz-retail-saudi-funding-trump-tailwinds/cZTc3BORIRN">media appearances</a>, including an interview with Fox News Chief Political Anchor Bret Baier and participation in a live discussion with Christopher Cuomo on NewsNation.Reflecting on conversations aired during a segment focused on cancer research and treatment, Soon-Shiong highlighted&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028173238338204093">on X</a> the importance of IL-15, the biological foundation of Anktiva, noting its ability to stimulate T cells, NK cells and memory T cells, which supports durable immune responses across multiple tumor types.Soon-Shiong also pointed to remarks from U.S. Food and Drug Administration (FDA) authorities that a validated mechanism of action can support additional indications, and highlighted the agency’s “plausible mechanism of action” pathway as a means to accelerate access to therapies such as IL-15. He added that results from the company’s Quilt trials in lung, breast, and pancreatic cancers showed that IL-15 has the potential to generate long-term immune memory.The founder also drew attention to combination approaches involving Anktiva and Merck’s Keytruda. He said checkpoint inhibitors such as Merck’s Keytruda work by removing the “brakes” on immune cells, while Anktiva helps grow and strengthen those immune cells. He said the combination could help patients respond if their cancer stops reacting to earlier immunotherapy.<h2 class="st-heading-2">Trial Progress Adds Momentum</h2>ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva combined with BCG in patients with early-stage bladder cancer who had not previously received standard BCG therapy.The study enrolled 366 patients and an early FDA-requested review indicated improved outcomes with the combination. After six months, 85% of patients receiving Anktiva with BCG remained cancer-free compared with 57% treated with BCG alone. At nine months, 84% of patients on the combination showed no recurrence, compared with 52% on standard therapy.The company expects to submit a biologics license application for the regimen by the fourth quarter of 2026. Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has also received authorizations in the UK, Europe and Saudi Arabia. Saudi regulators recently granted accelerated approval for the therapy in combination with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX shifted from ‘extremely bullish’ to ‘bullish’ amid a 65% decline in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_3d2d4b49a6.webp" alt="ibrx ss.png" width="975" height="143"><figcaption>IBRX sentiment and message volume as of March 2 | Source: Stocktwits</figcaption></figure>One user noted that Keytruda currently generates more than $30 billion in annual sales and is set to face patent expiration in 2028, describing Anktiva as a “better” product that could benefit from that shift. They urged traders to “buy and hold” the stock.<stembedurl>https://stocktwits.com/Johann1011/message/646276968</stembedurl>Another user said, “I look forward to tomorrow's trading day. Things look promising for IBRX!!”<stembedurl>https://stocktwits.com/BullriderNkg/message/646274508</stembedurl>IBRX stock has skyrocketed nearly 400% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong announces newest initiatives for Cancer MoonShot 2020 at Hyatt Regency Boston on October 26, 2016. (Photo by Darren McCollester/Getty Images for NantHealth, Inc.)

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

Equity

Promising Biotech Stocks To Research - March 1st

Danaher, Vertex Pharmaceuticals, Moderna, argenex, United Therapeutics, ImmunityBio, and Medpace are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Shares Up 2.4% - Still a Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 2.4% - What's Next...

Promising Biotech Stocks To Consider - February 27th

Danaher, Vertex Pharmaceuticals, argenex, ImmunityBio, and Moderna are the five Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly...

ImmunityBio (NASDAQ:IBRX) Director Barry Simon Sells 75,000 Shares

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) Director Barry Simon sold 75,000 shares of the company's stock in a transaction dated Tuesday, February 24th. The shares were sold at an average...

ImmunityBio to Provide a Business Update and Review Financial Results for FY 2025 on Tuesday, March 3, 2026

ImmunityBio, Inc. (NASDAQ: IBRX), today announced that it will host a live conference call at 1:30 p.m. Pacific Time on Tuesday, March 3, 2026, to provide a business update, including progress across...

<ul class="summary-bullets"><li>Retail traders speculated the appearances could signal policy-linked, funding or other major developments.</li><li>The media spotlight comes just after ImmunityBio completed enrollment in a key Phase 2 trial showing improved cancer-free outcomes with Anktiva plus BCG.</li><li>Soon-Shiong also criticized the chemotherapy-driven cancer care model on The Daily Show, calling it shaped by big pharma companies.</li></ul>ImmunityBio Inc. (IBRX) is drawing fresh retail attention late Thursday ahead of two prime-time television appearances by founder&nbsp;and executive chairman, Patrick Soon-Shiong, on Friday, with investors speculating that the back-to-back interviews could signal upcoming developments tied to policy, funding, or regulatory catalysts.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> edged higher in Thursday’s regular session, recovering from its steepest selloff since December 2024. However, shares slipped about 0.7% in extended trading. The stock has surged more than 380% year to date.<h2 class="st-heading-2">IBRX Founder Heads To Fox, NewsNation</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2027174340970807445">confirmed on X</a> that he will appear in an interview with Fox News Chief Political Anchor Bret Baier and later participate in a live discussion with Christopher Cuomo on&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/NewsNation/status/2027061086352978014">NewsNation</a> the same evening. “Important conversation with Brett. Will be an interesting Friday evening!” Soon-Shiong wrote. He&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2027173524805218443">added</a> about the NewsNation appearance: “Will be an important discussion. Live event. Please listen in.”<h2 class="st-heading-2">Retail Speculation Builds Ahead Of Interviews</h2>The dual media appearances have triggered a wave of speculation among retail traders. On Stocktwits, retail sentiment for IBRX was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_a83eb4f5ae.webp" alt="ibrx ss.png" width="972" height="145"><figcaption>IBRX sentiment and message volume as of February 26 | Source: Stocktwits</figcaption></figure>Some traders pointed to Baier’s role and suggested the interview could involve government-related developments. “Brett Baier is Fox News’ chief political anchor, so Dr. Pat must have some politically juicy news regarding the current U.S. federal government,” one user&nbsp;<a href="https://stocktwits.com/arnolddiver/message/646062575">said</a>, adding that the NewsNation segment featuring federal agency workers raised questions about why it would be aired live.<stembedurl>https://stocktwits.com/arnolddiver/message/646062575</stembedurl>Others highlighted the reach of the appearances and the back-to-back scheduling. “Dr Pat on Fox News with Bret Baier tomorrow… then with Chris Cuomo on NewsNation,” one investor&nbsp;<a href="https://stocktwits.com/arnolddiver/message/646050381">posted</a>. “Baier has a massive audience… Cuomo talks as if his segment is a major expose… Can’t wait what’s about to be revealed.”<stembedurl>https://stocktwits.com/arnolddiver/message/646050381</stembedurl>Several users suggested the timing could signal a broader development. “Something cooking for tomorrow night,” one user&nbsp;<a href="https://stocktwits.com/Jeslane1378/message/646061978">said</a>, noting the significance of Soon-Shiong appearing on a network with a large audience.Another investor&nbsp;<a href="https://stocktwits.com/kcajsnikrep/message/646059527">linked</a> the media push to potential funding developments. “What do you think? Tomorrow Saudi news drops involving non-dilutive funding… is it better to do all this on a Friday to majorly squeeze shorts?”Some traders framed the appearances as part of a broader strategy. “Too bad it is on a Friday evening, but maybe some savvy investors will study over the weekend and jump on board Monday,” one user&nbsp;<a href="https://stocktwits.com/ADDTed/message/646059176">wrote</a>.Others expected a major announcement. “I’m going with something big is going to drop tomorrow,” one post&nbsp;<a href="https://stocktwits.com/LB19/message/646059060">said</a>, suggesting the dual interviews were designed for maximum impact.Additional posts reflected growing anticipation among retail traders. “Load up people! Full blown exposure tomorrow night,” one user&nbsp;<a href="https://stocktwits.com/Thorbig/message/646059024">said</a>. “Dr P going to drop a bomb PR tomorrow morning,” another user wrote.Some investors also pointed to the timing after market close. “Two big cancer shows on Friday after the market is closed… Monday might just be the biggest jump ever,” one trader&nbsp;<a href="https://stocktwits.com/RoyalFlushIBRX/message/646058566">said</a>.<h2 class="st-heading-2">Trial Progress Supports Momentum</h2>The media appearances come just a day after ImmunityBio said it has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-ibrx-stock-rising-today-anktiva-bcg-trial-results/cZTGaHXRIbM">completed enrollment</a> ahead of schedule in its Phase 2 Quilt 2.005 trial, evaluating Anktiva combined with BCG in patients with early-stage bladder cancer who have not previously received standard BCG treatment.The study included 366 patients, and an early review requested by the U.S. Food and Drug Administration showed that adding Anktiva to standard BCG therapy helped patients stay cancer-free for longer.After six months, 85% of patients receiving Anktiva with BCG still showed no signs of cancer, compared with 57% of those treated with BCG alone. After nine months, 84% of patients on the combination remained cancer-free versus 52% on BCG alone. ImmunityBio expects to submit a biologics license application for the therapy by the fourth quarter of 2026.The company’s immunotherapy has continued to gain global traction. Anktiva is already approved in combination with BCG for bladder cancer in the U.S., and has received authorizations in the U.K., Europe and Saudi Arabia. Saudi regulators last month also granted accelerated approval for the therapy in combination with a checkpoint inhibitor for metastatic non-small cell lung cancer.Meanwhile, a recent regulatory filing showed Soon-Shiong continues to hold a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunity-bio-founder-reaffirms-grip-as-stock-plunges-in-worst-selloff-since-2024-after-massive-rally/cZR66FWRIb3">controlling 66.3%</a> stake in ImmunityBio, underscoring his influence as the company heads into the ASCO Genitourinary Cancers Symposium between Thursday and Saturday.<h2 class="st-heading-2">Founder Flags Big Pharma Influence</h2>Soon-Shiong also flagged his appearance on The Daily Show with Jon Stewart last year&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2027070280619700509">on X</a>, where he argued that modern cancer care remains overly dependent on chemotherapy. He said that the model took shape through decades of alignment between government research bodies and big pharma companies.“And we as Americans, and as America, have trained the world, together with a big pharma, about chemotherapy, because it's a money-making machine,” Soon-Shion said.He had discussed how many widely used cancer drugs were developed from chemical warfare research and tested in immune-deficient models, and warned that traditional treatments can suppress the body’s natural killer cells and T-cells.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Ignites Retail Frenzy Ahead Of Founder’s Prime-Time TV Blitz — Traders Bets On Saudi Funding And Trump Tailwinds

ImmunityBio Inc. (IBRX) is drawing fresh retail attention late Thursday ahead of two prime-time television appearances by founder and executive chairman, Patrick Soon-Shiong, on Friday.

Founder Patrick Soon-Shiong is set for back-to-back prime-time interviews on Fox News and NewsNation on Friday.

$IBRX Q4 &#39;25 Earnings Results &amp; Recap

ImmunityBio expects significant increases in R&amp;D and operating expenses for the foreseeable future due to development efforts. Commercial launch of ANKTIVA in metastatic NSCLC is planned within 60 days in Saudi Arabia.

Stocktwits

ImmunityBio Inc

 Q4 '25 Earnings Results & Recap

ImmunityBio expects significant increases in R&D and operating expenses for the foreseeable future due to development efforts. Commercial launch of ANKTIVA in metastatic NSCLC is planned within 60 days in Saudi Arabia.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$IBRX Q4 &#39;25 Earnings Results &amp; Recap

ImmunityBio anticipates needing additional financing to fund operations, clinical trials, and commercialization of its approved product and other candidates, expecting operating expenses to increase substantially as development efforts accelerate.

 Q4 '25 Earnings Results & Recap

ImmunityBio anticipates needing additional financing to fund operations, clinical trials, and commercialization of its approved product and other candidates, expecting operating expenses to increase substantially as development efforts accelerate.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Stocktwits Polls

Traders eagerly anticipate a major short squeeze, expecting significant price movements as bears are forced to cover their positions amidst high conviction.

Speculation mounts around imminent funding and expanded approvals from Saudi Arabia, signaling significant international growth potential for the company.

Anticipation builds for tomorrow's business update and earnings call, with high expectations for significant news or revised guidance.

Excitement surrounds Anktiva, hailed as a super drug and a new paradigm in cancer treatment with broad therapeutic potential.

Current Price	$10.44
Prev Close	$9.78
Open	$9.64
Dividend Yield	0.00%
50-Day Moving Average	$5.13
Beta	1.96
Avg. Volume	52.17M
PE Ratio	-25.09

52-Week High	$12.43
52-Week Low	$1.83
Market Capitalization	$10.06B
EPS (Annual)	-$0.382
Price to Book	-19.77
Revenue Per Employee	$163,947.90

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc